Scott-edil Advance Research Laboratories & Educati

Scott-Edil Advance Research Laboratories & Education Limited (SEARLE) is an Indian pharmaceutical company specializing in the manufacturing of generic formulations, particularly antibiotics. Incorporated on June 4, 2009, under the Corporate Identification Number (CIN) U24232CH2009PLC031649, the company is headquartered in Chandigarh, India. As of the latest available data, SEARLE has an authorized capital of ₹40 crore and a paid-up capital of ₹39.48 crore. The company operates as a public limited entity, with a promoter holding of 92.83% and public shareholders holding 4.10% as of the fiscal year 2024. SEARLE's product portfolio includes a range of pharmaceutical formulations such as tablets, capsules, syrups, and injections, with a focus on cephalosporin and beta-lactam antibiotics.

SEARLE operates a manufacturing facility located in Baddi, Himachal Pradesh, India. This plant specializes in the production of various pharmaceutical formulations, including tablets, capsules, dry powder and liquid injectables, dry syrups, oral liquids, ophthalmic solutions, ointments, creams, gels, dietary protein, and food supplements. The facility is certified by the World Health Organization for Good Manufacturing Practices (WHO GMP), ensuring adherence to international quality standards.

The leadership team at SEARLE comprises several key individuals:

• Vaishali Aggarwal: Managing Director, appointed on June 4, 2009.

• Sanjeev Kumar: Director, appointed on June 4, 2009.

• Munish Kumar: Director, appointed on August 1, 2017.

• Prince Vohra: Chief Financial Officer (CFO), appointed on October 11, 2021.

• Balram Krishan: Additional Director, appointed on January 11, 2010.

• Pushkin Sharma: Director, appointed on October 18, 2017.

SEARLE's presence in regulated markets such as the United States, European Union, United Kingdom, Australia, and Japan is not explicitly detailed in the available sources. The company's manufacturing facility in Baddi, Himachal Pradesh, is certified by the World Health Organization for Good Manufacturing Practices (WHO GMP), which is a prerequisite for market access in many regulated regions. However, specific regulatory filings, approvals, and market access statuses in these countries are not provided in the available information.

SEARLE's export data indicates a total export value of $7.9 million USD across 294 shipments, with a portfolio concentration of 100% in advanced antibiotics. The company's focus on cephalosporin and beta-lactam antibiotics positions it well for market penetration in emerging regions. While the available data does not specify the company's presence in Africa, Latin America, or Southeast Asia, the WHO GMP certification of its manufacturing facility suggests potential for market access in these regions.

SEARLE's export portfolio is entirely concentrated in advanced antibiotics, indicating a strategic focus on this therapeutic area. The company's manufacturing facility is WHO GMP certified, which may facilitate market access in various regions. However, the lack of detailed information on specific market entries and regulatory approvals suggests that SEARLE's geographic diversification strategy may be in the early stages. Further expansion into diverse markets could mitigate concentration risks associated with its current portfolio.

Specific information regarding SEARLE's FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history is not available in the provided sources. The company's manufacturing facility in Baddi, Himachal Pradesh, is WHO GMP certified, which is a prerequisite for market access in many regulated regions. However, without explicit FDA approvals or registrations, SEARLE's direct market access in the United States remains uncertain.

SEARLE's manufacturing facility in Baddi, Himachal Pradesh, is certified by the World Health Organization for Good Manufacturing Practices (WHO GMP), ensuring adherence to international quality standards. The available information does not specify whether the facility holds European Union Good Manufacturing Practice (EU GMP) certification or European Directorate for the Quality of Medicines & HealthCare (EDQM) status. Obtaining EU GMP certification would enhance SEARLE's credibility and facilitate market access within the European Union.

SEARLE's manufacturing facility in Baddi, Himachal Pradesh, is certified by the World Health Organization for Good Manufacturing Practices (WHO GMP), which is recognized by the Central Drugs Standard Control Organisation (CDSCO) in India. The available information does not provide details on specific CDSCO manufacturing licenses, state drug controller approvals, or export No Objection Certificates (NOCs) held by SEARLE. These regulatory approvals are essential for the company's operations and export activities within India.

The available information does not detail any recent regulatory actions such as Form 483 observations, warning letters, or import alerts issued to SEARLE. The company's manufacturing facility in Baddi, Himachal Pradesh, is certified by the World Health Organization for Good Manufacturing Practices (WHO GMP), indicating compliance with international quality standards. However, without explicit information on recent regulatory actions, a comprehensive assessment of SEARLE's regulatory compliance history cannot be made.

SEARLE operates in the competitive and fragmented pharmaceutical industry, focusing on the manufacturing of generic formulations, particularly antibiotics. The company's product portfolio includes a range of pharmaceutical formulations such as tablets, capsules, syrups, and injections, with a focus on cephalosporin and beta-lactam antibiotics. While specific market share data is not available, SEARLE's emphasis on contract manufacturing for domestic and foreign pharmaceutical companies, as well as government entities, positions it as a significant player in the generic pharmaceutical sector.

SEARLE's key differentiators include its specialization in the manufacturing of generic formulations, particularly antibiotics, and its focus on contract manufacturing for domestic and foreign pharmaceutical companies, as well as government entities. The company's manufacturing facility in Baddi, Himachal Pradesh, is certified by the World Health Organization for Good Manufacturing Practices (WHO GMP), ensuring adherence to international quality standards. These factors contribute to SEARLE's competitive advantage in the pharmaceutical industry.

SEARLE's current strategic direction focuses on the manufacturing of generic formulations, particularly antibiotics, and contract manufacturing for domestic and foreign pharmaceutical companies, as well as government entities. The company's manufacturing facility in Baddi, Himachal Pradesh, is certified by the World Health Organization for Good Manufacturing Practices (WHO GMP), ensuring adherence to international quality standards. While specific information on future strategic plans is not available, SEARLE's emphasis on quality manufacturing and contract manufacturing positions it well for continued growth in the generic pharmaceutical sector.

SEARLE's manufacturing facility in Baddi, Himachal Pradesh, is certified by the World Health Organization for Good Manufacturing Practices (WHO GMP), ensuring adherence to international quality standards. The company's focus on contract manufacturing for domestic and foreign pharmaceutical companies, as well as government entities, indicates a reliable track record in fulfilling large-scale production requirements. However, specific data on export volume and consistency, as well as other reliability indicators, are not available in the provided sources.

Importers should verify the following certifications to ensure product quality and regulatory compliance: